The struggle of a patient suffering from a rare, severe, and progressive neuromuscular genetic disorder has touched the heart of Health Minister Datuk ...

Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees ...

Biogen reported positive Phase 2/3 DEVOTE study results for high dose nusinersen in spinal muscular atrophy, published in Nature Medicine. The data support safety and effectiveness across a broad SMA ...

Administration in the mid-to-high dose cohorts of the gene therapy trial will pause pending further evaluation.

Biogen Inc. (BIIB) stock reached a 52-week high, peaking at 190.34 USD, underscoring a robust performance over the past year. The stock has experienced a notable 31.14% increase over the last 12 ...

The singer, 34, recently addressed the devastating prognosis that Ocean Jade and Story Monroe, aged nine months, may not live ...

Since taking over as CEO of the Cambridge biotech more than three years ago, Chris Viehbacher has cut hundreds of jobs and reduced expenses, in part by removing drugs from its research pipeline.

Biogen topped fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment ...

Treatment with a high-dose regimen of Spinraza safely improved motor function in children with SMA, according to data from the DEVOTE trial.

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

Jesy Nelson hasn’t given up hope that her twin daughters, Ocean Jade and Story Monroe, will overcome a muscle disease they were diagnosed with a month ago. The former Little Mix singer was recently a ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis ...